ImmunoGen to Sell Residual Royalty Rights for Kadcyla (ado-trastuzumab emtansine) to OMERS

 ImmunoGen to Sell Residual Royalty Rights for Kadcyla (ado-trastuzumab emtansine) to OMERS

ImmunoGen to Sell Residual Royalty Rights for Kadcyla (ado-trastuzumab emtansine) to OMERS

Shots:
  • Immunogen to receive $65M as total deal value and OMERS to get royalties on sales of Kadcyla
  • In 2015, Immunogen & IRH collaborated for Kadcyla’s royalty for $200M, where IRH received 100% royalties on sales and will own rights till the amount reaches to $235M or $260M. Immunogen to hold 85% of royalties while 15% owned by Genentech (acc. to the 2000 deal of Immunogen & Genetech) on
    reaching the threshold amount
  • Kadcyla (ado-trastuzumab emtansine) is an ADC developed for delivering CT directly to HER2-positive cancer cells and is approved in 104 countries including the US and EU for HER2-positive metastatic breast cancer

Click here to read full press release/ article | Ref: Immunogen | Image: Cytomx

Shiwani Sharma

Shiwani Sharma was Senior Editor at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post